The aim of this study is to determine whether fasting and post-prandial glucagon secretion is suppressed by gliclazide in patients with HNF1-/4-alpha MODY. Participants will undergo an oral glucose tolerance test (OGTT) before and after omitting their gliclazide medication for 3 days.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
Clinical Research Unit, OCDEM, Churchill Hospital
Oxford, Oxfordshire, United Kingdom
Change in plasma glucagon from baseline (0min)
Change in the concentration of plasma glucagon from baseline during an oral glucose tolerance test (OGTT), while on gliclazide and after a washout period.
Time frame: 0min, 30min, 60min, 90min and 120min during 75g oral glucose tolerance test.
Change in plasma c-peptide from baseline (0min)
To determine whether changes in post-prandial glucagon levels correlate with changes in c-peptide levels in HNF1-/4-alpha MODY patients on and off gliclazide.
Time frame: 0min, 30min, 60min, 90min and 120min during 75g oral glucose tolerance test.
Change in plasma non-esterified fatty acids (NEFA) from baseline (0min)
To determine whether changes in post-prandial glucagon levels correlate with changes in NEFA levels in HNF1-/4-alpha MODY patients on and off gliclazide.
Time frame: 0min, 30min, 60min, 90min and 120min during 75g oral glucose tolerance test.
Continuous glucose monitor recordings
To assess the blood glucose variability on and off gliclazide treatment (only for participants who opt to take part in this optional component).
Time frame: 12 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.